BioSpace News Archive

Albireo Pharma, Inc., a rare pediatric liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo’s common stock and restricted stock units representing the opportunity to acquire 3,500 shares of Albireo’s common stock.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, announced that on September 2, 2021, the compensation committee of BridgeBio’s board of directors granted 29 new employees restricted stock units for an aggregate of 61,210 shares of the Company’s common stock.

Minerva Neurosciences, Inc. today announced Dr. Jay Saoud’s retirement and transition to an advisory role and Dr. Ramana Kuchibhatla’s appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021.

Brickell Biotech, Inc. today announced that it is scheduled to participate in two upcoming virtual investment conferences, including the H.C. Wainwright 23rd Annual Global Investment Conference

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC).

Wave Life Sciences Ltd. today announced it will highlight its ADAR-mediated RNA editing capability at its 2021 Analyst and Investor Research Webcast taking place Tuesday, September 28, 2021 at 10:00 a.m. EDT.

Coherus BioSciences, Inc. today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at the European Society for Medical Oncology Congress 2021.

Anixa Biosciences, Inc. announced today that Dr. Amit Kumar , Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15 , 2021.

Lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from accelerated throughput and improved sensitivity to meet rapidly changing regulatory requirements and provide the fast responses needed for tackling emerging human and environmental health risks.

Principal investigators, laboratories, and proteomics researchers in academia, biopharma and contract research organizations can now benefit from an all-in-one nano-, capillary- and micro-flow liquid chromatography system.